Recent advances in SARS-CoV-2 main protease inhibitors: from nirmatrelvir to future perspectives
A Citarella, A Dimasi, D Moi, D Passarella, A Scala… - Biomolecules, 2023 - mdpi.com
The main protease (Mpro) plays a pivotal role in the replication of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus …
L Tian, T Qiang, X Yang, Y Gao, X Zhai, K Kang… - European Journal of …, 2024 - Elsevier
Although no longer a public health emergency of international concern, COVID-19 remains
a persistent and critical health concern. The development of effective antiviral drugs could …
a persistent and critical health concern. The development of effective antiviral drugs could …
Inhibitors of SARS-CoV-2 main protease (Mpro) as anti-coronavirus agents
A Zagórska, A Czopek, M Fryc, J Jończyk - Biomolecules, 2024 - pmc.ncbi.nlm.nih.gov
The main protease (Mpro) of SARS-CoV-2 is an essential enzyme that plays a critical part in
the virus's life cycle, making it a significant target for developing antiviral drugs. The …
the virus's life cycle, making it a significant target for developing antiviral drugs. The …
Design, synthesis, X-ray crystallography, and biological activities of covalent, non-Peptidic inhibitors of SARS-CoV-2 Main protease
M Ashraf-Uz-Zaman, TK Chua, X Li, Y Yao… - ACS Infectious …, 2024 - ACS Publications
Highly contagious SARS-CoV-2 coronavirus has infected billions of people worldwide with
flu-like symptoms since its emergence in 2019. It has caused deaths of several million …
flu-like symptoms since its emergence in 2019. It has caused deaths of several million …
On the origins of SARS-CoV-2 main protease inhibitors
YL Janin - RSC Medicinal Chemistry, 2024 - pubs.rsc.org
In order to address the world-wide health challenge caused by the COVID-19 pandemic, the
3CL protease/SARS-CoV-2 main protease (SARS-CoV-2-Mpro) coded by its nsp5 gene …
3CL protease/SARS-CoV-2 main protease (SARS-CoV-2-Mpro) coded by its nsp5 gene …
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions
AM Shawky, FA Almalki, HA Alzahrani… - European Journal of …, 2024 - Elsevier
Since 2020, many compounds have been investigated for their potential use in the treatment
of SARS-CoV-2 infection. Among these agents, a huge number of natural products and FDA …
of SARS-CoV-2 infection. Among these agents, a huge number of natural products and FDA …
Advanced technologies for screening and identifying covalent inhibitors
Y Guo, A Tong, Y Wang - TrAC Trends in Analytical Chemistry, 2024 - Elsevier
Covalent inhibitors, forming reversible or irreversible covalent bonds with nucleophilic
groups in target protein active sites, effectively inhibit protein function for therapeutic …
groups in target protein active sites, effectively inhibit protein function for therapeutic …
Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors
The COVID-19 pandemic is caused by SARS-CoV-2, a highly transmissible and pathogenic
RNA betacoronavirus. Like other RNA viruses, SARS-CoV-2 continues to evolve with or …
RNA betacoronavirus. Like other RNA viruses, SARS-CoV-2 continues to evolve with or …
Structure-Based Lead Optimization of Enterovirus D68 2A Protease Inhibitors
Enterovirus D68 (EV-D68) virus is a nonpolio enterovirus that typically causes respiratory
illness and, in severe cases, can lead to paralysis and death in children. There is currently …
illness and, in severe cases, can lead to paralysis and death in children. There is currently …
Targeting the Main Protease (Mpro, nsp5) by Growth of Fragment Scaffolds Exploiting Structure-Based Methodologies
N Altincekic, N Jores, F Löhr, C Richter… - ACS Chemical …, 2024 - ACS Publications
The main protease Mpro, nsp5, of SARS-CoV-2 (SCoV2) is one of its most attractive drug
targets. Here, we report primary screening data using nuclear magnetic resonance …
targets. Here, we report primary screening data using nuclear magnetic resonance …